Skip to main content

Market Overview

Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials

Share:
Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials

After Belite Bio Inc (NASDAQ:BLTE) reported results, its stock has been under pressure.

The company reported its results amid an exciting earnings season. Here are some key analyst takeaways.

HC Wainwright On Belite Bio

Analyst Yi Chen maintained a Buy rating and price target of $100.

Belite Bio reported a net loss of $36.1 million, or $1.18 per share, "slightly higher than our estimated loss of $35.7M," Chen said in a note. Last month, the company announced positive results from "a pre-specified interim analysis of the pivotal Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease (STGD1) patients," he added.

The trial can now proceed without any modifications and does not need an increase in the sample size, the analyst stated. If the DRAGON trial, which is likely to be completed by the fourth quarter of 2025, shows data that is similar to or better than the Phase 2 data, "tinlarebant could potentially become the first FDA-approved treatment for STGD1," he further wrote.

Check out other analyst stock ratings.

Cantor Fitzgerald On Belite Bio

Analyst Jennifer Kim reiterated an Overweight rating on the stock.

Belite Bio reported cash and investments of $145.1 million and gross proceeds of $15 million, Kim said. Enrollment in the DRAGON II trial is ongoing in adolescent STGD1, she added.

The Phase III DRAGON trial is expected to be completed by the fourth quarter of 2025 and the data could be released by early 2026, the analyst stated. "Over the next ~12-18 months, we expect share appreciation to be driven by updates across tinlarebant’s P3 programs in both STGD1 (DRAGON, DRAGON II) and geographic atrophy (PHOENIX)," she wrote.

BLTE Price Action: Shares of Belite Biohad declined by 0.46% to $67.50 at the time of publication on Tuesday.

Read More:  

Photo: Shutterstock

 

Related Articles (BLTE)

View Comments and Join the Discussion!

Posted-In: Cantor Fitzgerald Expert Ideas HC WainwrightAnalyst Color Earnings Top Stories Analyst Ratings Tech

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com